Stock market news live updates: Wall Street rallies as Oxford/AstraZeneca vaccine shows promise

Wall Street rose at the opening bell, adding to recent gains as investors weighed new COVID-19 infections — which are leading to rising deaths and a record number of hospitalizations across the U.S. — against the rapidly unfolding timetable for the deployment of a vaccine.

Markets have been broadly encouraged by the steady flow of positive news over a coronavirus cure. On Monday, University of Oxford and AstraZeneca (AZN) revealed that their candidate demonstrated efficacy of 70.4% in two large-scale trails, If a lower dose is used, then a second, full dose, the efficacy is up to 90%, the company said.

Those developments came on the heels of Pfizer (PFE) and BioNTech (BNTX) announcing plans to file for an emergency use authorization with the U.S. Food and Drug Administration, which would allow them to have their vaccine used in the U.S. starting in December.

Expectations for a relatively quick vaccine rollout have boosted the broader market, as well as prospects for 2021 growth, while leading investors to unwind technology-heavy “stay at home” bets that previously bolstered key stocks like Netflix (NFLX), Amazon (AMZN), Zoom (ZOOM) and other names. Both the Dow (^DJI) and S&P 500 (^GSPC) notched record closing highs last week, as traders rode a wave of exuberance sparked by the vaccine news.

However, the near term outlook remains clouded by the relentless scourge of more COVID-19 infections, and the inability of Washington’s warring parties to agree on stimulus. The current wave of the virus is swamping the darkest days of March and April, threatening to overshadow the holidays and drag on growth.

“This winter will be grim, and we believe the economy will contract again in 1Q, albeit at ‘only’ a 1.0% annualized rate,” JPMorgan Chase’s economics team wrote in a lengthy research note last week.

“The economy no longer has that tailwind; instead it now faces the headwind of increasing restrictions on activity. The holiday season—from Thanksgiving through New Year’s—threatens a further increase in cases,” the bank said.

Story continues

Last week, Senate Minority Leader Chuck Schumer (D-N.Y.) said that Senate Majority Leader Mitch McConnell (R-Ky.) agreed to restart talks on a deal. The news momentarily sparked a boost for stocks, and fanned hopes that a lame-duck session could produce a bargain ahead of President-elect Joe Biden’s inauguration in January.

However, the Senate has already adjourned for the Thanksgiving holiday, and will not meet again for another full session until the end of the month. That narrows the window of opportunity for new legislation to get passed.

Meanwhile, economists are weighing whether a brewing dispute between the Treasury Department and the Federal Reserve will unsettle markets. The central bank said on Friday it would return unused emergency money allocated by the Treasury, a day after U.S. Treasury Secretary Steven Mnuchin ordered the Fed to allow nine of its 13 liquidity facilities to close on December 31.

“The extent to which any committed funds would eventually be returned remains unclear, but even if it happened, we do not think that [general account] or reserve balances (or issuance) would be affected,” Goldman Sachs said in a research note over the weekend.

“Of course, on further stimulus, there would be additional issuance, but we see this as separate from the Fed facility discussion. On the margins, non-continuation of some backstops may increase the odds of the Fed compensating in other areas,” the bank added.

—

9:45 a.m. ET: Manufacturing sector expands at historic pace: ISM

U.S. business activity expanded at the fastest rate in more than five years in November, led by the quickest pickup in manufacturing since September 2014, Reuters reports. The survey was the latest indication the economy continues to extricate itself from the COVID-19 recession, even with new infections soaring.

—

9:35 a.m. ET: Analyst: AstraZeneca ‘will never be licensed in the U.S.’

Stocks are rallying at the opening bell, but SVB Leerink has poured cold water on the Oxford/AstraZeneca news that got markets on a bull run. In a sharply worded analysis, the bank accused AZN of trying to “embellish” its results, and offered several reasons why “this product will never be licensed in the US:”

—

9:30 a.m. ET: Stocks pop at the opening bell, riding wave of vaccine hopes

Here were the main moves in markets, as of 9:30 a.m. ET:

• S&P 500 (^GSPC): 3,581.33, +23.79 (+0.67%)

• Dow (^DJI): 29,493.43, +229.95 (+0.79%)

• Nasdaq (^IXIC): 11,927.83, +72.86 (+0.61%)

• Crude (CL=F): $42.83 per barrel, +$0.41 (+0.97%)

• Gold (GC=F): 14,863.60 per ounce, -$8.80 (-0.47%)

• 10-year Treasury (^TNX): +0.18 bps to yield 0.847%

—

7:15 a.m. ET: ‘We should all be smiling this morning’

In a research note Monday, Deutsche Bank called the Oxford/AstraZeneca vaccine news “a big deal” that puts the world on track for wide-scale inoculation to COVID-19 by the middle of 2021:

—

7:00 a.m E.T.: Stock futures gain as vaccine news boosts sentiment

Here were the main moves in equity markets as of early Monday:

• S&P 500 futures (ES=F): 3,572.00, +17.75 (+0.50%)

• Dow futures (YM=F): 29,378.00, +166.00 (+0.57%)

• Nasdaq futures (NQ=F): 11,946.75, +41.00 (+0.34%)

—

6:20 p.m. ET Sunday: Stock futures open near the unchanged mark

Here were the main moves in equity markets, as of 6:20 p.m. ET Sunday:

• S&P 500 futures (ES=F): 3356.00, +1.75

• Dow futures (YM=F): 29202, -10

• Nasdaq futures (NQ=F): 11926.75, +22

—

Follow Yahoo Finance on Twitter, Facebook, Instagram, Flipboard, LinkedIn, and reddit.

Find live stock market quotes and the latest business and finance news

For tutorials and information on investing and trading stocks, check out Cashay

View Article Origin Here